Plasma concentrations of angiogenetic factors and angiogenetic inhibitors in patients with ductal pancreatic neoplasms. A pilot study by R. Pezzilli et al.
Clin Chem Lab Med 2011;49(6):1047–1051  2011 by Walter de Gruyter • Berlin • Boston. DOI 10.1515/CCLM.2011.159
2010/683
Article in press - uncorrected proof
Plasma concentrations of angiogenetic factors and
angiogenetic inhibitors in patients with ductal pancreatic
neoplasms. A pilot study
Raffaele Pezzilli1,*, Dario Fabbri1, Massimiliano M.
Corsi3, Andrea Imbrogno1, Alessandra Barassi4,
Antonio M. Morselli-Labate1, Giada Dogliotti3,
Riccardo Casadei2, Roberto Corinaldesi1 and
Gianvico Melzi d’Eril4
1 Department of Digestive Diseases and Internal Medicine,
Sant’Orsola-Malpighi Hospital, University of Bologna,
Bologna, Italy
2 Department of Emergency, General and Transplant
Surgery, Sant’Orsola-Malpighi Hospital, University of
Bologna, Bologna, Italy
3 Institute of General Pathology, University of Milan,
Milan, Italy
4 Department of Medicine, Surgery and Dentistry,
University of Milan, Milan, Italy
Abstract
Background: The aim of the study was to evaluate the cir-
culating concentrations of vascular endothelial growth factor
(VEGF), vascular endothelial growth factor receptor-2
(VEGFR-2), vascular endothelial growth factor-D (VEGF-D)
and endostatin in patients with intraductal papillary mucinous
neoplasm (IPMN), and in those with ductal adenocarcinomas.
Methods: Sixty patients (32 males, 28 females, mean age
69.3"11.3 years) were enrolled: 31 (51.7%) had IPMNs and
29 (48.3%) had histologically confirmed pancreatic adeno-
carcinomas. Thirty blood donors were also studied as con-
trols. In all study subjects, the concentrations of VEGF,
VEGF-D, VEGFR-2, and endostatin were determined using
enzyme-linked immunosorbent assays.
Results: Serum concentrations of VEGF, VEGF-D, and
VEGFR-2 were significantly higher in patients with pancre-
atic ductal adenocarcinoma and those with IPMNs compared
with healthy subjects, while endostatin was significantly
higher only in patients with pancreatic ductal adenocarci-
noma compared with healthy subjects. Within the group of
patients, VEGFR-2 was significantly higher in patients with
ductal adenocarcinoma compared to those with IPMNs. The
sensitivity and the specificity of VEGFR-2 in differentiating
patients with ductal adenocarcinomas from those with IPMN
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at a cut-off range of 4003–4034 pg/mL was 86.2% and
54.8%, respectively.
Conclusions: IPMNs have serum VEGFR-2 concentra-
tions different from those in patients with ductal adenocar-
cinomas. However, serum VEGFR-2 cannot be routinely
utilized to differentiate IPMNs from pancreatic ductal
adenocarcinomas.
Keywords: angiogenesis inducing agents; endostatins;
pancreatic neoplasms; vascular endothelial growth factor
receptor-2.
Introduction
Intraductal papillary mucinous neoplasms (IPMNs) of the
pancreas are a group of slow-growing tumors which can be
cured surgically in most patients (1). There is little data
regarding the inflammation processes associated with this
disease. We have recently demonstrated that serum tumor
necrosis factor receptor-1 is elevated in patients with IPMNs
and in those with pancreatic adenocarcinomas, suggesting
high apoptotic activity in both groups of patients studied (2).
Among the causes of the aggressive behavior of ductal exo-
crine pancreatic tumors, angiogenesis appears to be essential
for tumor growth and the development of metastases and
angiogenetic factors, such as vascular endothelial growth
factor (VEGF), which seem to play a pivotal role (3). VEGF
specifically interacts with receptor tyrosine kinases, such as
vascular endothelial growth factor receptor-2 (VEGFR-2),
which are mainly expressed by endothelial cells, but also by
some cancer cells, and they seem to be responsible for the
poor prognosis of various tumors (4). Furthermore, vascular
endothelial growth factor-D (VEGF-D) is one of the major
factors associated with the growth of lymphatic endothelial
cells (5). Finally, endostatin is a potent inhibitor of angio-
genesis, and increased concentrations of this protein may be
associated with cancer progression (6). Thus, several active
and passive strategies appear to be adopted by tumor cells
to determine the spread of the tumor from the primary site.
All these substances have been studied in pancreatic ductal
adenocarcinoma, mainly in pathological specimens, but not
in patients with pancreatic IPMNs. Thus, the main aim of
the present study was to evaluate the circulating concentra-
tions of VEGF, VEGF-D, VEGFR-2 and endostatin in malig-
nant diseases of the pancreas, such as IPMNs and pancreatic
adenocarcinomas. We also evaluated the concentrations of
these molecules in comparison to CA 19-9.
Brought to you by | Università degli Studi di Milano (Università degli Studi di Milano)
Authenticated | 172.16.1.226
Download Date | 7/4/12 4:02 PM
1048 Pezzilli et al.: Inflammation and pancreatic neoplasms
Article in press - uncorrected proof
Table 1 Demographic and clinical characteristics of patients with malignant pancreatic diseases according to the final diagnosis (data are
reported as mean"SD or frequencies).
Pancreatic intraductal Pancreatic p-Value
papillary mucinous neoplasm adenocarcinoma
(no. 31) (no. 29)
Gender 1.000a
Males 17 (54.8%) 15 (51.7%)
Females 14 (45.2%) 14 (48.3%)
Age, years 69.8"10.2 68.7"12.5 0.594b
Body mass index (BMI), kg/m2 23.0"3.1 21.1"2.6 -0.025b
BMI classes 0.022c
Underweight, -18.5 kg/m2 0 5 (17.2%)
Normal, 18.5–24.9 kg/m2 28 (90.3%) 23 (79.3%)
Preobese, 25–29.9 kg/m2 2 (6.5%) 1 (3.4%)
Obese, 30 kg/m2 or more 1 (3.2%) 0
Localization 0.166d
Head 19 (61.3%) 26 (89.7%)
Head-body 1 (3.2%) 0
Body 3 (9.7%) 1 (3.4%)
Body/tail 1 (3.2%) 1 (3.4%)
Tail 4 (12.9%) 1 (3.4%)
Diffuse 3 (9.7%) 0
Metastases 2 (6.5%) 21 (72.4%) -0.001a
Pain 8 (25.8%) 27 (93.1%) -0.001a
Jaundice 4 (12.9%) 15 (51.7%) 0.002a
Diabetes 11 (35.5%) 24 (82.8%) -0.001a
Pancreatic exocrine insufficiency, 9 (29.0%) 9 (31.0%) 1.000a
fecal elastase-1-200 mg/g
Pancreatic surgery 8 (25.8%) 14 (48.3%) 0.108a
aFisher’s exact test. bKruskal-Wallis test. cLinear-by-linear association x2. dPearson x2.
Materials and methods
Patients
Consecutive patients, 18 years of age or older, who were admitted
to the Unit for the Study of Pancreatic Diseases of Sant’Orsola-
Malpighi Hospital of Bologna (Italy) for exocrine pancreatic neo-
plasms between October 2007 and December 2009 were eligible for
inclusion in the study.
A total of 60 patients (32 males, 28 females, mean age 69.3"
11.3 years) were enrolled: 31 (51.7%) had IPMNs and 29 (48.3%)
had histologically-confirmed pancreatic adenocarcinoma; the demo-
graphic and clinical characteristics of the patients studied are report-
ed in Table 1. The body mass index (BMI) was stratified ac-
cording to the World Health Organization (WHO) classification (7),
and pancreatic insufficiency was defined as a fecal elastase-1 con-
centration of -200 mg/g (8). At the time of the study, none of the
patients had had any treatment for their disease. Of the 31 patients
with IPMNs, 16 (51.6%) had branch type IPMNs and the remaining
15 (48.4%) had main duct type IPMNs.
As shown in Table 1, the two groups of patients were not statis-
tically different regarding gender (ps1.000), age (ps0.594) and
localization of the tumor (ps0.166) whereas the BMI of the patients
with pancreatic ductal adenocarcinoma was significantly lower than
that of patients having an IPMN (p-0.025). In addition, the fre-
quency of metastases (p-0.001), pain (p-0.001), jaundice
(ps0.002) and diabetes (p-0.001) were significantly higher in
patients with pancreatic ductal adenocarcinoma than in those having
IPMNs. The frequency of pancreatic exocrine insufficiency at the
time of the study, and the frequency of patients who underwent
pancreatic surgery after the diagnosis, were not different be-
tween the groups of patients studied (ps1.000 and ps0.108,
respectively).
Finally, 30 blood donors were also studied as healthy controls (17
males, 13 females; mean age 59.7"8.1; ps0.825 and p-0.001 vs.
the gender and the age of patients, respectively).
Methods
Fasting blood specimens were obtained in the morning from each
subject enrolled. Laboratory personnel were unaware of the clinical
diagnoses or the details of the patients’ clinical histories. Serum
was stored at –208C until analysis.
Concentrations of VEGF, VEGF-D, VEGFR-2, and endostatin
were determined using enzyme-linked immunosorbent assays (ELI-
SA) (R&D System, Minneapolis, MN, USA). This analysis employs
a quantitative sandwich enzyme immunoassay technique. A mono-
clonal antibody specific for this molecule was pre-coated onto a
microplate. After dilution, standards and samples were pipetted into
the wells. After washing away any unbound substances, an enzyme-
linked monoclonal antibody specific for each of these molecules
was added to the wells. After removing any unbound antibody-
enzyme reagent, substrate solution was added to the wells and color
developed in proportion to the amount of our specific molecules.
The reaction was stopped with 50 mL HCl and the intensity of the
color was measured at 450 nm. The dilution factor was recorded in
order to calculate the concentration of VEGF, VEGF-D, VEGFR-2
and endostatin in the samples.
The maximum intra- and inter-assay coefficients of variation
(CVs) were 5.44% and 7.30% for VEGF (20 determinations at each
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Table 2 Circulating concentrations of the various substances studied in the three groups of subjects. Data are reported as mean"SD.
Pancreatic intraductal Pancreatic p-Valuea Healthy
papillary mucinous adenocarcinoma subjects
neoplasm (no. 31) (no. 29) (no. 30)
VEGF, pg/mL 1210"1004 1175"664 0.348 328"173
p vs. healthy subjects p-0.001 p-0.001 –
VEGF-D, pg/mL 854"493 878"500 0.994 342"58
p vs. healthy subjects p-0.001 p-0.001 –
VEGFR-2, pg/mL 4216"794 5031"1142 0.006 2313"722
p vs. healthy subjects p-0.001 p-0.001 –
Endostatin, ng/mL 79.4"61.4 128.9"105.4 0.058 46.9"17.1
p vs. healthy subjects ps0.108 p-0.001 –
CA 19-9, U/mL 776"3686 1206"2450 0.002 11"8
p vs. healthy subjects ps0.014 p-0.001 –
aPancreatic intraductal papillary mucinous neoplasm vs. pancreatic adenocarcinoma.
Table 3 Area under the curve (AUC) and standard error of AUC (SE) for VEGFR-2 and CA 19-9 for differentiating patients with pancreatic
adenocarcinoma from those with pancreatic intraductal papillary mucinous neoplasms (IPMNs). Sensitivity and specificity were evaluated
at the best cut-off range.
AUC"SE Sensitivity, % Specificity, % Cut-off range
VEGFR-2 0.707"0.067 86.2 54.8 4003–4034 pg/mL
CA 19-9 0.727"0.070 72.4 74.2 63–89 U/mL
concentration of 50, 250 and 900 pg/mL), 4.20% and 7.47% for
VEGF-D (20 determinations at each concentration of 250, 900 and
2000 pg/mL), 3.57% and 6.54% for VEGFR-2 (20 determination at
each concentration of 2000, 5000 and 10,000 pg/mL), 5.50% and
6.57% for endostatin (20 determination at each concentration of 10,
50 and 100 ng/mL), respectively. The detection limits were 9 pg/
mL for VEGF, 11.4 pg/mL for VEGF-D, 7 pg/mL for VEGFR-2,
and 0.023 ng/mL for endostatin. Finally, we also assayed CA 19-9
using an electrochemical luminescence immunoassay (CA 19-9,
Roche, Milan, Italy; reference limits 0–37 U/mL).
Ethics
The study was approved by the Clinical Committee of the Depart-
ment of Internal Medicine of Sant’Orsola Hospital of Bologna (Ita-
ly) and was performed in accordance with the Helsinki Declaration
of the World Medical Association. All subjects gave written in-
formed consent to participate in the study.
Statistical analysis
Means, standard deviations (SD), and frequencies were used as
descriptive statistics. Data were analyzed by means of non-para-
metric tests: the Kruskal-Wallis test, the Fisher’s exact test, the Pear-
son x2, and the linear-by-linear association x2. The forward
multivariate linear regression was used in order to identify the clin-
ical variables independently related to the various analytes studied.
Receiver operating characteristic (ROC) curve analysis was used to
differentiate patients with pancreatic adenocarcinomas from those
with pancreatic IPMNs. The best cut-off values were chosen to be
the values of the assays which maximized the likelihood ratio (LR)
obtained using the following formula: LRs(Probability of true
positiveqProbability of true negative)/(Probability of false
positiveqProbability of false negative) (9). The SPSS (SPSS Inc.,
Chicago, IL, USA, Version 13.0) statistical package was used to
analyze the data. Two-tailed p-values of -0.05 were considered
statistically significant.
Results
The mean"SD values of VEGF, VEGF-D, VEGFR-2,
endostatin and CA 19-9 in the three groups of patients stud-
ied are reported in Table 2.
Serum concentrations of VEGF, VEGF-D, VEGFR-2 and
CA 19-9 were significantly higher both in patients with pan-
creatic ductal adenocarcinoma and in those with IPMN com-
pared with healthy subjects, while endostatin was signi-
ficantly higher in pancreatic ductal adenocarcinoma patients
only compared with healthy subjects. Within the group of
patients, VEGFR-2 and CA 19-9 were significantly higher
in patients with pancreatic ductal adenocarcinoma than in
those with IPMN, while no significant differences were
observed for VEGF, VEGF-D and endostatin. For this rea-
son, we calculated the best cut-off vales for both VEGFR-2
and CA 19-9 in order to differentiate patients with pancreatic
ductal adenocarcinoma from those with IPMN. As reported
in Table 3, the area under the curve (AUC) and the standard
error of AUC (SE) for VEGFR-2 and CA 19-9 were
0.707"0.067 and 0.727"0.070, respectively. Using a cut-
off range of 4003–4034 pg/mL for VEGFR-2, the sensitivity
and the specificity of this chemokine in differentiating
patients with pancreatic adenocarcinoma from those with
IPMN was 86.2% and 54.8%, respectively, while, at a cut-
off range of 63–89 U/mL, CA 19-9 had a sensitivity of
72.4% and a specificity of 74.2%.
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Table 4 Circulating concentrations of the various substances studied in the two groups of patients with pancreatic intraductal papillary
mucinous neoplasms (IPMNs). Data are reported as mean"SD.
IPMN main duct type IPMN branch type p-Value
(no. 15) (no. 16)
VEGF, pg/mL 1102"1150 1311"871 0.089
VEGF-D, pg/mL 760"285 941"628 0.607
VEGFR-2, pg/mL 4204"834 4227"781 0.843
Endostatin, ng/mL 88.4"60.1 71.0"63.3 0.323
CA 19-9, U/mL 1483"5292 113"241 0.220
Regarding the clinical variables, the 23 patients with
metastasis (two patients with IPMN and 21 patients with
pancreatic adenocarcinoma) had serum concentrations of
VEGFR-2, endostatin and CA 19-9 that were significantly
higher (VEGFR-2: 5107"1216 pg/mL, ps0.012; endosta-
tin: 131.0"98.2 ng/mL, ps0.046; CA 19-9: 2163"4852
U/mL, ps0.015) than the 37 patients without metastasis
(VEGFR-2: 4302"810 pg/mL, ps0.012; endostatin: 86.1"
78.2 ng/mL, CA 19-9: 251"492 U/mL), whereas the 35
patients with diabetes (11 patients with IPMN and 24
patients with pancreatic adenocarcinoma) had serum concen-
trations of endostatin and CA 19-9 significantly higher
(endostatin: 125.1"100.3 ng/mL, ps0.031; CA 19-9: 1557"
4017 U/mL, ps0.007) than the 25 patients without diabetes
(endostatin: 72.8"57.2 ng/mL, CA 19-9: 181"296 U/mL).
In addition, CA 19-9 was significantly higher in the 35
patients (eight patients with IPMN and 27 patients with pan-
creatic adenocarcinoma) with pain (1019"2265 U/mL) vs.
the 25 patients without pain (934"4102 U/mL, ps0.026).
Multivariate analysis showed that the type of the tumor
(IPMN or pancreatic adenocarcinoma) only was significantly
related to VEGFR-2 serum concentrations (ps0.002). Also,
the presence of diabetes only was significantly related to
endostatin serum concentrations (ps0.022). In contrast, no
clinical variables entered the analyses for VEGF, VEGF-D.
In contrast, the presence of metastases (ps0.002) and jaun-
dice (ps0.024) were independently and significantly related
to CA 19-9 serum concentrations.
Finally, within the group of 31 patients with IPMN, no
significant differences in serum concentrations of VEGF,
VEGF-D, VEGFR-2, and endostatin were found between the
15 patients with main duct type IPMN and the 16 patients
with branch type IPMN (Table 4).
Discussion
Patients with pancreatic adenocarcinoma have a poor out-
come, while those with IPMN of the pancreas have slow
growing neoplasms which can be cured surgically in most
patients (1). The differences between the two neoplasms are
also confirmed by the clinical data of our study. In fact,
patients with ductal adenocarcinoma had a frequency of pain,
diabetes, jaundice and metastases significantly higher than
those with IPMN, as well as having significantly lower BMI.
At present, there are no data regarding the angiogenetic fac-
tors released by pancreatic IPMNs. Thus, we performed the
present study in order to evaluate VEGF, VEGF-D, VEGFR-2
and endostatin in patients with malignant chronic diseases of
the pancreas, such as pancreatic adenocarcinoma and IPMN,
because a better understanding of the circulating concentra-
tions of angiogenetic and antiangiogenetic factors would be
helpful in developing immunotherapeutic approaches to pan-
creatic neoplasms (10) since there is a lack of conventional
immune therapeutic options for these patients, especially for
those having IPMN.
For the first time, we comparatively evaluated serum con-
centrations of angiogenetic and antiangiogenetic factors in
patients with pancreatic ductal adenocarcinoma and in
patients with pancreatic IPMN. We found that serum con-
centrations of VEGF, VEGF-D, VEGFR-2 and endostatin
were significantly higher in patients with ductal adenocar-
cinoma than in healthy subjects, and these results are similar
to those previously reported for VEGF (3) and endostatin
alone (6). Furthermore, data on VEGF-D and VEGFR-2 have
previously been reported only on pancreatic tissue and we
now report these data for blood. Tumor angiogenesis is often
the consequence of an angiogenetic imbalance in which
proangiogenetic factors predominate over antiangiogenetic
factors (11). The fact that we found that all the circulating
angiogenetic factors are increased seems to support the
hypothesis that there is an inappropriate response to tumor
invasiveness by the host. This is also supported by the fact
that VEGFR-2, which is a marker of poor prognosis in var-
ious tumors including pancreatic cancer (4, 6), shows high
serum concentrations in patients with pancreatic ductal ade-
nocarcinoma rather than in those with IPMNs. This is also
supported by the finding that patients with advanced cancer,
i.e., those with metastasis and those with diabetes, had high
serum concentrations of this protein. Multivariate analysis
showed the type of tumor (IPMN or pancreatic adenocarci-
noma) was the only clinical variable independently related
to VEGFR-2 serum concentrations. However, in clinical
practice, VEGFR-2 cannot be utilized as a marker to distin-
guish patients with pancreatic ductal adenocarcinomas from
those with IPMN, because even if the sensitivity was 86.2%,
the specificity was quite low (54.8%).
Also, of interest, is the fact that considering only patients
with IPMN, those patients having main duct type had similar
values of both proangiogenetic and antiangiogenetic factors
compared with patients with branch type IPMN.
Regarding CA 19-9, this marker is also not useful for dif-
ferentiating patients with pancreatic ductal adenocarcinoma
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from those with IPMN because the sensitivity and specificity
were quite low at 72.4% and 74.2%, respectively. Our data
confirm previous studies suggesting that CA 19-9 determi-
nation is not recommended for use as a screening test for
pancreatic neoplasia (12, 13) and, in particular, the multi-
variate analysis demonstrates that the presence of metastases
and jaundice were independently related to CA 19-9 serum
concentrations.
In conclusion, our data further suggest that an IPMN is
one of the precursors of ductal adenocarcinoma, and it has
a pattern of angiogenetic factors different from ductal ade-
nocarcinoma. However, these markers, such as CA 19-9,
cannot be utilized to routinely differentiate IPMNs from pan-
creatic ductal adenocarcinomas.
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